Business
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
CAMBRIDGE, Mass., May 19, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further derisking its continued development for the chronic treatment of neuropsychiatric disorders.
About this update from Enveric Biosciences, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/0403e0ec2c35417d107a15aef56b5ed6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HUmAXPKfuBjvrq7zV59l1Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/0403e0ec2c35417d107a15aef56b5ed6","width":960,"height":480},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/cqieqmrRM3viOcgXYVYj4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/0403e0ec2c35417d107a15aef56b5ed6","width":640,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/D4TqkBGUiC.7i_JhvjbpOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/0403e0ec2c35417d107a15aef56b5ed6","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Analysis showed no photoreactive potential for EB-003, further derisking its continued development for the treatment of neuropsychiatric disorders including depression, anxiety and PTSD.","length":186,"tagName":"p"},{"type":"text","content":"Phototoxicity testing is a part of preclinical safety assessment evaluating whether a novel pharmaceutical compound could become harmful when exposed to UV light.","length":162,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., May 19, 2026--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced promising results from preclinical in vitro experiments evaluating the risk for phototoxicity, which indicated no photoreactive potential for EB-003, further derisking its continued development for the chronic treatment of neuropsychiatric disorders.","length":536,"tagName":"p"},{"type":"text","content":"This represents another preclinical safety assessment milestone for Enveric’s neuroplastogen EB-003, the first known compound designed to selectively engage both 5-HT2A and 5-HT1B receptors. EB-003 is intended to deliver fast-acting, durable antidepressant and anxiolytic effects with outpatient convenience.","length":308,"tagName":"p"},{"type":"text","content":"Photo...